Graham Capital Management L.P. Purchases 123,610 Shares of Kura Oncology, Inc. $KURA

Key Points

• Graham Capital Management L.P. increased its stake in Kura Oncology by 242.6% in the first quarter, now owning approximately 0.20% of the company valued at $1,152,000.
• Other institutional investors, such as Millennium Management LLC and Armistice Capital LLC, also significantly boosted their holdings in Kura Oncology during recent quarters.
• Kura Oncology's stock has seen a 6.0% increase recently, but the company reported an EPS loss of $0.75, missing analyst estimates by $0.90.

Graham Capital Management L.P. grew its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 242.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 174,559 shares of the company's stock after acquiring an additional 123,610 shares during the period. Graham Capital Management L.P. owned about 0.20% of Kura Oncology worth $1,152,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Armistice Capital LLC grew its holdings in Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after purchasing an additional 772,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kura Oncology by 2.7% in the first quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock worth $32,658,000 after buying an additional 129,337 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after purchasing an additional 1,521,954 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 35.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock worth $12,419,000 after purchasing an additional 372,196 shares during the last quarter. Finally, Prosight Management LP increased its holdings in Kura Oncology by 87.9% in the fourth quarter. Prosight Management LP now owns 1,325,000 shares of the company's stock valued at $11,541,000 after buying an additional 619,891 shares in the last quarter.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded down $0.12 during midday trading on Monday, hitting $8.10. The company had a trading volume of 1,196,386 shares, compared to its average volume of 1,463,391. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $21.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The business's 50 day simple moving average is $6.66 and its two-hundred day simple moving average is $6.56. The stock has a market cap of $703.43 million, a PE ratio of -3.61 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million during the quarter, compared to analysts' expectations of $64.95 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KURA. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. Mizuho decreased their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Finally, JMP Securities lowered their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.10.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.